Translationally controlled tumor protein (TCTP) plays a pivotal role in cardiomyocyte survival through a Bnip3-dependent mechanism

Wenqian Cai¹, Takayuki Fujita¹, Yuko Hidaka¹, Huiling Jin¹, Kenji Suita¹, Mayo Shigeta², Hiroshi Kiyonari²,³, Masanari Umemura¹, Utako Yokoyama¹, Junichi Sadoshima⁴ and Yoshihiro Ishikawa¹

Abstract
Prevention of cardiomyocyte death is an important therapeutic strategy for heart failure. In this study, we focused on translationally controlled tumor protein (TCTP), a highly conserved protein that is expressed ubiquitously in mammalian tissues, including heart. TCTP plays pivotal roles in survival of certain cell types, but its function in cardiomyocytes has not been examined. We aimed to clarify the role of TCTP in cardiomyocyte survival and the underlying mechanism. Here, we demonstrated that downregulation of TCTP with siRNA induced cell death of cardiomyocytes with apoptotic and autophagic features, accompanied with mitochondrial permeability transition pore (mPTP) opening. TCTP loss did not induce cell death of cardiac fibroblasts. Bcl-2/adenovirus E1B 19-kDa interacting protein 3 (Bnip3) was found to mediate the TCTP-loss-induced cardiomyocyte death. In exploring the clinical significance of the TCTP expression in the heart, we found that DOX treatment markedly downregulated the protein expression of TCTP in cultured cardiomyocytes and in mouse heart tissue. Exogenous rescue of TCTP expression attenuated DOX-induced cardiomyocyte death. In mice, cardiomyocyte-specific overexpression of TCTP resulted in decreased susceptibility to DOX-induced cardiac dysfunction, accompanied with attenuated induction of Bnip3. Dihydroartemisinin, a pharmacological TCTP inhibitor, induced development of heart failure and cardiomyocyte death in control mice, but not in mice with cardiomyocyte-specific TCTP overexpression. Our findings revealed TCTP has a pivotal role in cardiomyocyte survival, at least in part through a Bnip3-dependent mechanism. TCTP could be considered as a candidate therapeutic target to prevent DOX-induced heart failure.

Introduction
Prevention of cardiomyocyte death is an important therapeutic strategy for heart failure¹,². The loss of cardiomyocytes induced by various stresses is a major cause of reduced cardiac performance. Numerous studies have revealed the involvement of several pathways, including catecholamine and p53-mediated signaling, in stress-induced cardiomyocyte death and subsequent development of heart failure²–¹¹. However, the major signaling pathway involved in the survival of cardiomyocytes has not been established.

In this study, we focused on translationally controlled tumor protein (TCTP), a highly conserved protein that is expressed ubiquitously in mammalian tissues including heart¹²,¹³. Recent reports, including our own, have revealed that TCTP plays important roles in various
cellular functions including cell survival, cell proliferation, tumorigenesis, allergic response, and pulmonary vascular remodeling. However, to our knowledge, there is no report on TCTP function in cardiomyocytes.

TCTP exerts its functions in a cell-type-dependent manner. It promotes cell survival and inhibits apoptosis in some types of normal cells and cancer cells. Several studies have demonstrated that TCTP deficiency results in early embryonic lethality characterized by increased apoptosis. In addition, TCTP silencing caused induction of DNA damage or apoptosis in several normal and cancer cell lines. These findings indicate that TCTP is a pro-survival molecule. However, the significance of TCTP in cell survival depends on the cell type and conditions. On the other hand, TCTP deficiency does not affect apoptotic sensitivity or proliferation of mouse embryonic fibroblasts. The percentage of TUNEL-positive cells in embryos at day 5.5 showed no difference between wild-type and TCTP-deficient mice. TCTP deletion in T cells caused no reduction in thymocyte numbers. In addition, an inverse relationship between TCTP expression and growth rate was found with an epithelial cell line.

In this study, we examined the role of TCTP in cardiomyocyte survival. We found that TCTP downregulation induced cardiomyocyte death, indicating that TCTP is a key player in cardiomyocyte survival. In addition, we identified Bcl-2/adenovirus E1B 19-kDa interacting protein 3 (Bnip3) as a mediator of TCTP-loss-induced cell death. Further, TCTP-loss-induced cardiomyocyte death had apoptotic and autophagic features accompanied with mPTP opening, which are features of Bnip3-induced cell death. TCTP and Bnip3 are both expressed in mitochondria. Recent studies have demonstrated that Bnip3 is involved in cardiomyocyte death in response to clinically important pathogenic stresses, including treatment with anthracycline antibiotics.

In exploring the clinical significance of TCTP expression in the heart, we found that doxorubicin (DOX) treatment markedly suppressed the protein expression of TCTP in cultured cardiomyocytes and mouse heart tissue. DOX is an anthracycline antibiotic, and is widely used in cancer therapy. However, its clinical usage has been limited by its serious cardiotoxicity. Approximately 10% of patients are reported to suffer cardiac side effects, which not only limit their activities of daily life, but also require dose reduction, reducing the effectiveness of treatment for malignancies. Thus, there is an urgent need for a strategy to prevent DOX-induced cardiac dysfunction.

Based on the above findings, we hypothesized that the maintenance of TCTP expression level could be an effective strategy to prevent DOX-induced cardiomyocyte death and cardiac dysfunction. Here, we tested this hypothesis by examining the role of TCTP in cardiomyocyte-specific TCTP-overexpressing mice, and by investigating the effect of dihydroartemisinin (DHA), a pharmacological TCTP inhibitor. Our results indicate a pivotal role of TCTP in cardiomyocyte survival, and also suggest that TCTP can prevent DOX-induced cardiac dysfunction.

Materials and methods

An expanded Materials and methods section is available in the Supplementary Materials and Methods.

Cell culture

Primary cultures of neonatal rat ventricular myocytes (NRVMs) and neonatal rat cardiac fibroblasts (NRCFs) were prepared from the heart of 3-day-old Wistar rats as previously described. H9C2 cells were seeded and cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) and a 1% solution of penicillin-streptomycin at 37 °C in 5% CO₂. The next day, the medium was replaced with serum-free medium.

Immunofluorescence microscopy

Primary NRVMs were seeded on coverslips. Mito Tracker Red (Thermo Fisher) was added to the medium 45 min before fixation. Cells were then fixed in 4% paraformaldehyde at room temperature for 15 min, permeabilized with 0.2% Triton X-100 for 5 min, and blocked with 5% BSA in PBS for 1 h. Cells were incubated with primary antibodies at 4 °C overnight, followed by 1 h incubation with secondary antibody (goat anti-rabbit AlexaFluor 488) and 5 min incubation with DAPI. Images were analyzed by deconvolution microscopy (Nikon).

Cell death assay

The staining solution contained 2 μM Calcein-AM (Dojindo) and 2 μM ethidium homodimer-1 (Takara Bio) in serum-free medium. Cells were gently washed twice and then incubated with the staining solution under 5% CO₂ in humidified air at 37 °C for 45 min. The live cells were stained with Calcein-AM (green) and dead cells with ethidium homodimer-1 (red). Cell death (%) was calculated from the numbers of live and dead cells.

Flow cytometry

Cells were washed twice with cold PBS and resuspended in Binding Buffer (BD). After incubation with APC Annexin V (BD) and 7-amino-actinomycin D (7-AAD) (BD) for 15 min at room temperature in the dark, apoptotic cells were quantified by flow cytometry. Annexin V-stained cells were considered to be apoptotic.
Mitochondrial permeability transition pore (mPTP) opening

Neonatal rat ventricular myocytes were incubated for 20 min with acetoxymethyl ester of Calcein-AM (1 μM) and then washed in the presence of CoCl₂ (1 mM) for another 20 min to remove the dye from the cytosolic compartment. The loss of Calcein-AM fluorescence was used as an indicator of mPTP opening.

Detection of Ad-LC3-GFP

NRVMs were transduced with adenovirus harboring LC3-GFP (Ad-LC3-GFP) as previously described. The fluorescence of GFP-LC3 was observed under a fluorescence microscope. The number of GFP dots was determined by counting fluorescent puncta from at least three independent myocyte preparations. At least 60 cells were scored for each group.

Mice

We generated TCTP transgenic mice (TCTP TG) with cardiac-specific overexpression of TCTP using α-myosin heavy chain (α-MHC) promoter on a C57BL/6 background (TCTP TG; Accession No. CDB0532T: http://www2.clst.riken.jp/arg/TG%20mutant%20mice%20list.html).

p53 knockout mice (p53 KO) (on a C57BL/6 background) were purchased from RIKEN BRC.

All animal experiments were conducted in accordance with the guidelines of the animal experiment committee of Yokohama City University and of Institutional Animal Care and Use Committee (IACUC) of RIKEN Kobe Branch.

Mouse models

DOX-induced heart failure

Two- to three-month-old male mice were given intraperitoneal injection of 3 mg/kg DOX three times a week up to a total dose of 24 mg/kg. At 5 weeks after the first injection, cardiac morphology and function were evaluated by echocardiography and catheterization.

ISO-induced heart failure model

Two- to three-month-old male C57BL/6 mice were given chronic ISO (Sigma–Aldrich) infusion via an osmotic mini-pump (DURECT Corporation) at a dose of 60 mg/kg/day for 2 or 7 days.

Transverse aortic constriction (TAC)-induced heart failure model

Two- to three-month-old male C57BL/6 mice were anesthetized with isoflurane vapor titrated to maintain the lightest anesthesia possible. On average, 1.5% vol/vol isoflurane vapor was required to maintain adequate anesthesia. The animals were ventilated via tracheal intubation with a tidal volume of 0.5 ml and a respiratory rate of 90 breaths per minute. The left side of the chest was opened at the second intercostal space, and TAC or sham operation was performed.

Echocardiography

Mice were anesthetized with inhaled isoflurane (1.5%) using an induction chamber. Echocardiography was performed as previously described.

Cardiac catheterization

Mice were anesthetized with inhaled isoflurane (1.5%) and a 1.4F catheter (Millar) was inserted into the LV through the carotid artery. Hemodynamic measurements were performed as previously described.

Histological analysis

Heart specimens were fixed with formalin, embedded in paraffin, and sectioned at 3.5 μm. Sections were deparaffinized and fibrosis was evaluated by Masson-trichrome staining using the Accustain Trichrome Stain Kit (Sigma–Aldrich). Apoptosis was determined by TUNEL staining using the DeadEnd fluorometric TUNEL system (Promega). Nuclei were stained with DAPI. The numbers of TUNEL-positive nuclei and total nuclei were counted.

Statistics

All data were expressed as mean ± standard error of the mean (S.E.M.). Comparison of data was performed using Student's t-test for two groups. Multiple comparisons were made using one-way analysis of variance (ANOVA) followed by Tukey’s test or two-way ANOVA followed by Bonferroni’s post hoc test. For all analytical studies, the criterion of significance was assigned as P < 0.05.

Results

TCTP expression in cardiomyocytes

We examined the TCTP protein expression level in cardiomyocytes and cardiac fibroblasts. The TCTP expression level per total protein was 1.8-fold greater in NRVMs than in NRCFs (Fig. 1a). In addition, the expression level in NRVMs was similar to those in the cancer cell lines for which a pivotal role of cardiomyocyte in cell survival has been reported (Fig. 1b). TCTP was widely localized in nucleus, mitochondria, and cytoplasm of cardiomyocytes (Fig. 1c).

TCTP downregulation resulted in cardiomyocyte death

In order to investigate the role of TCTP in cardiomyocyte survival, we downregulated TCTP expression with two different siRNAs (TCTP siRNA #1 and #2) in NRVMs. The dose-dependent effect of these TCTP siRNAs was confirmed by western blotting (Fig. 2a, c). Both
TCTP siRNA #1 and #2 induced cardiomyocyte death in a dose-dependent manner (Fig. 2b, d). Furthermore, DHA, a pharmacological TCTP inhibitor, induced cardiomyocyte death accompanied by TCTP downregulation (Fig. 2e, f). Interestingly, however, TCTP siRNA did not reduce the viability of NRCFs (Fig. S1), suggesting that the role of TCTP in cell survival is cell-type-dependent.

TCTP downregulation caused cardiomyocyte death through a Bnip3-dependent mechanism

To investigate the mechanism of TCTP-loss-induced cardiomyocyte death, we examined the characteristics of cardiomyocyte death, including annexin V expression, DNA fragmentation, mPTP opening, autophagosome accumulation, and LC3B II expression, in NRVMs after siRNA silencing of TCTP (Fig. 3d–g; Figs. S2b, S3d–f). All of these features were induced by TCTP silencing, suggesting that the TCTP-loss-induced cardiomyocyte death shows apoptotic and autophagic features, accompanied with mPTP opening. Recent reports indicate that Bnip3-induced cell death shows the same features. Here, we found that TCTP downregulation increased Bnip3 expression at both the mRNA (1.8-fold) and protein levels (1.9-fold) in NRVMs (Fig. 3a, b; Fig. S3a).

Therefore, to examine the role of Bnip3 induction in the TCTP-loss-induced cardiomyocyte death, we downregulated Bnip3 expression in NRVMs by treatment with siRNAs (Figs. S2a, S3b). Bnip3 silencing significantly attenuated TCTP-loss-induced cardiomyocyte death (TCTP siRNA vs. TCTP+Bnip3 siRNA: 22.8% vs. 14.3%), apoptosis (TCTP siRNA vs. TCTP+Bnip3 siRNA: 32.5% vs. 15.6%), mPTP opening (Relative fluorescence intensity/cell: TCTP siRNA vs. TCTP+Bnip3 siRNA: 0.1 vs. 0.5), and autophagosome accumulation (LC3-GFP puncta/cell: TCTP siRNA vs. TCTP+Bnip3 siRNA: 4.7 vs. 1.8) (Fig. 3c–g; Fig. S2b). Similar results were obtained with another Bnip3 siRNA (Bnip3 siRNA #2) (Fig. S3c, d, f). These findings suggested that Bnip3 induction is a major step in the pathway of TCTP-loss-induced cardiomyocyte death.

In this experiment, we did not observe significant attenuation of TCTP siRNA #2-induced mPTP opening by Bnip3 siRNA #2 (Fig. S3e). TCTP siRNA #1 downregulated TCTP expression more effectively than TCTP siRNA #2. Consistently with this, induction of mPTP opening by TCTP siRNA #1 was greater than that by TCTP siRNA #2 (Fig. 3e; Fig. S3e, g). Thus, the difference of downregulating effect between these two TCTP siRNAs may account for the difference in the results. Bnip3 may play a role in TCTP-loss-induced mPTP opening when TCTP is highly suppressed.

Among several proteins that are reported to regulate Bnip3 expression, we found NF-kB protein expression was 54% decreased by TCTP siRNA (Fig. S4a). On the other hand, no significant change was observed in the expression of p53, Bax, E2F1, or FOXO3a (Fig. S4b–f). These findings suggested that NF-kB may be involved in the TCTP-loss-induced increase of Bnip3 expression.
Fig. 2 TCTP downregulation resulted in cardiomyocyte death. a–d NRVMs were transfected with various doses of TCTP siRNA #1 or siRNA #2 for 72 h. e, f NRVMs were treated with various concentrations of DHA for 48 h. a, c, e Protein expression of TCTP and GAPDH was analyzed after TCTP siRNAs transfection or DHA treatment \((n = 4)\). b, d, f Cell death was determined by calcein-AM/ethidium homodimer-1 staining \((n = 4)\). Live and dead cells were distinguished by calcein-AM (green) and ethidium homodimer-1 (red) staining, respectively. Scale bar, 200 \(\mu m\). *\(P < 0.05\), **\(P < 0.01\), ***\(P < 0.001\) vs 0. One-way ANOVA followed by Tukey’s test.
Fig. 3 (See legend on next page.)
Overall, our results indicate that TCTP loss caused cardiomyocyte death at least in part through a Bnip3-dependent mechanism.

Since there is controversy regarding the role of autophagy in cardiomyocyte death\(^{1,46,57}\), we examined its role in the TCTP-loss-induced cardiomyocyte death. In our studies, inhibition of autophagy by 3-MA or Atg5 siRNA resulted in suppression of TCTP-loss-induced cardiomyocyte death (Fig. S5a, b), suggesting that the autophagy under these conditions was maladaptive for cell survival.

Next, we examined the mechanism of the TCTP-loss-induced autophagosome accumulation. Autophagosome accumulation can result from either enhancement of autophagosome formation or inhibition of degradation\(^{48}\). BFA, an inhibitor of vacuolar H\(^+\)-ATPase, disrupts autophagy processing by inhibiting autophagosome-lysosome fusion. In the presence of BFA, TCTP silencing induced no increase in autophagosome number or LC3BII protein expression in cardiomyocytes (Fig. 3h, i). These findings indicate that TCTP-loss-induced autophagosome accumulation was caused by inhibition of autophagosomal degradation, as has been observed in DOX-treated cardiomyocytes\(^{48}\).

**DOX treatment suppressed cardiac TCTP expression both in vitro and in vivo**

To investigate the clinical significance of TCTP expression in the heart, we examined the TCTP expression level in cardiomyocytes and heart tissues after DOX treatment. We found that DOX treatment markedly suppressed the TCTP mRNA and protein expression in cultured NRVMs (Fig. 4a, b). In addition, TCTP expression was suppressed in the heart tissues after both acute (22.6%) and chronic (32.4%) DOX treatment (Fig. 4c, d). These findings indicated that TCTP downregulation may be involved in DOX-induced heart failure. On the other hand, conversely, TCTP was upregulated after chronic isoproterenol (ISO) infusion or chronic pressure overload induced by transverse aortic constriction (TAC) in mice (Fig. S6a–d). In accordance with this, TCTP mRNA and protein expression were increased by ISO treatment in cultured cardiomyocytes (Fig. S6e–g).

p53, a major tumor suppressor, is involved in the development of various physiological dysfunctions, including cardiac diseases such as heart failure\(^{2,49}\), ischemic heart disease\(^{50}\), and DOX-induced heart failure\(^{41,51,52}\). It was demonstrated that TCTP and p53 negatively regulate each other’s functions and expression levels\(^{15,53,54}\). To examine the role of p53 in DOX-induced TCTP downregulation, we examined cardiac TCTP expression in the heart of p53-deficient mice (p53 KO) after DOX treatment. The DOX-induced TCTP downregulation was attenuated in p53 KO mice (WT vs. p53KO: −31.9% vs. −14.8%) (Fig. 4e), indicating that DOX suppressed TCTP expression at least in part through a p53-dependent mechanism. In addition, we found that the DOX-induced increase of Bnip3 expression was attenuated in p53 KO mouse heart (WT vs. p53KO: 5.8-fold vs. 2.8-fold) (Fig. 4f). Overall, these findings suggest that p53 is involved in DOX-induced TCTP loss and enhancement of Bnip3 expression.

**Exogenous supplementation of TCTP rescued cardiomyocytes from DOX-induced death**

To investigate the significance of DOX-induced TCTP loss in relation to DOX’s cardiotoxicity, we examined the effect of exogenous supplementation of TCTP on DOX-induced cell death in a cardiomyocyte cell line, H9C2. DOX treatment induced TCTP downregulation (31% lower) and cell death (CTRL vs. DOX: 1.6% vs. 11.4%) (Fig. 5), while exogenous supplementation of TCTP via plasmid transfection significantly suppressed DOX-induced cell death (pcDNA vs. mTCTP: 11.4% vs. 5.7%) (Fig. 5a, b). Importantly, just supplementary exogenous expression, which rescues the DOX-induced TCTP loss, was enough to significantly inhibit DOX-induced cell death, suggesting that TCTP downregulation may play a key role in DOX-induced cardiomyocyte death.
Fig. 4 DOX treatment suppressed TCTP expression both in vivo and in vitro. a, b mRNA level (a) and protein expression (b) of TCTP in NRVMs treated with or without DOX (0.1 μM) for different times (n = 4). c C57BL/6 mice were treated intraperitoneally with DOX (20 mg/kg) or normal saline (CTRL). Protein expression of TCTP and GAPDH in hearts was analyzed after DOX treatment for 48 h (n = 7–8). d C57BL/6 mice were treated intraperitoneally with DOX (3 mg/kg) or normal saline. DOX was administered three times a week, with a total dose of 24 mg/kg. At 5 weeks after the first injection, protein expression of TCTP and GAPDH in hearts was analyzed (n = 4). e, f WT and p53 KO mice were treated intraperitoneally with DOX (20 mg/kg) or normal saline (CTRL). Protein expression of TCTP (e) (n = 11–12), Bnip3 (f) (n = 5–6) and GAPDH in hearts was analyzed after 48 h. *P < 0.05, **P < 0.01, ***P < 0.001. One-way ANOVA followed by Tukey’s test (a, b) or unpaired, two-tailed Student’s t-test (c, d, e) or two-way ANOVA followed by Bonferroni’s test (e, f).
Cardiomyocyte-specific TCTP overexpression protected mice against DOX-induced cardiac dysfunction

To examine the role of TCTP in cardiomyocytes in vivo, we generated TCTP transgenic mice (TCTP TG #1 and #2) with cardiac-specific overexpression of TCTP using α-MHC promoter. TCTP expression in the heart was significantly greater in TCTP TG #1 mice than in WT mice (Fig. 6b; Fig. S7a–h).

There were no significant differences between WT mice and TCTP TG #1 mice in cardiac morphology or functions at baseline (Fig. 6a, d–f; Table S2).

We examined the effect of TCTP overexpression in cardiomyocytes on the DOX-induced cardiac dysfunction in mice. DOX-induced cardiac dysfunction was significantly attenuated in TCTP TG #1 mice (Fig. 6d–f; Table S2). Indexes of cardiac function, including LVEF and maximum and minimum dP/dt, were significantly better in DOX-treated TCTP TG mice than in WT mice (LVEF: WT vs. TCTP TG: 61.9% vs. 68.2%; Max dP/dt: WT vs. TCTP TG: 7592 mmHg/s vs. 10581 mmHg/s; Min dP/dt: WT vs. TCTP TG: −6962 mmHg/s vs. −10191 mmHg/s). These findings indicate that TCTP overexpression prevented DOX-induced cardiac dysfunction. The effect of TCTP overexpression on DOX-induced cardiac dysfunction was confirmed in TCTP TG #2 mice, another mouse line of TCTP TG with milder overexpression of TCTP (Fig. S8a–d; Table S3). DOX treatment caused a significant increase of apoptotic cell death in the heart (Fig. 6g). Importantly, in accordance with the results of functional analysis, apoptotic cell death was significantly attenuated in hearts from TCTP TG #1 compared with WT (WT vs. TCTP TG: 0.49% vs. 0.29%). In addition, we found that Bnip3 expression was increased, accompanied with downregulation of TCTP, in the hearts of both WT and TCTP TG #1 mice. However, the increase of Bnip3 expression was significantly smaller in hearts from TCTP TG #1 mice (WT vs. TCTP TG: 2.0-fold vs. 1.2-fold) (Fig. 6c), suggesting that TCTP loss may be related to DOX-induced Bnip3 expression.

Treatment with DHA, a pharmacological inhibitor of TCTP, resulted in cardiac dysfunction in mice

To investigate the effect of TCTP loss on cardiac function in vivo, we treated mice with DHA, a pharmacological inhibitor of TCTP (Fig. 2e). DHA suppressed TCTP and enhanced Bnip3 protein expression in mouse heart. In addition, the extent of Bnip3 induction by DHA was less in TCTP TG #1 than in WT mice (Fig. 7a), indicating that DHA-induced TCTP loss may be involved in the DHA-induced increase of Bnip3 expression. Importantly, we found that DHA treatment caused heart failure. In addition, cardiac overexpression of TCTP significantly attenuated the DHA-induced left ventricular dysfunction (LVEF: WT vs. TCTP TG: 58.9% vs. 67.5%; Max dP/dt: WT vs. TCTP TG: 7670 mmHg/s vs. 10262 mmHg/s; Min dP/dt: WT vs. TCTP TG: −6705 mmHg/s vs. −8162 mmHg/s) (Fig. 7b–d; Table S4). DHA also caused a significant increase of apoptotic cell death in the heart, and this was significantly attenuated by TCTP overexpression in cardiomyocytes (WT vs. TCTP TG: 0.11% vs. 0.07%) (Fig. 7e). These findings indicate that loss of TCTP may cause cardiomyocyte death and cardiac dysfunction in vivo.
**Fig. 6** Cardiomyocyte-specific TCTP overexpression protected mice against DOX-induced cardiac dysfunction. 

**a** Representative images of sections from WT and TCTP TG mouse hearts stained with hematoxylin and eosin (HE) (top) and Masson trichrome (middle). Immunohistochemistry (IHC) with TCTP antibody in heart tissues of WT and TCTP TG mice (bottom). Scale bar, 50 μm. 

**b** TCTP and GAPDH protein expression in the left ventricle of WT and TCTP TG #1 mice \( (n = 5) \). 

**c** WT and TCTP TG mice were treated intraperitoneally with DOX (3 mg/kg) or normal saline (CTRL). DOX was administered three times a week, with a total dose of 24 mg/kg. Protein expression levels of TCTP, Bnip3, and GAPDH in the hearts were analyzed \( (n = 4 – 5) \). 

**d** - **g** five weeks after the first injection, LVEF was evaluated by echocardiography \( (d) \) \( (n = 6 – 9) \). Max dP/dt \( (e) \) and Min dP/dt \( (f) \) were evaluated by cardiac catheterization \( (n = 6 – 7) \). 

**g** Cardiac apoptosis in the myocardium was assessed by TUNEL assay in heart sections from WT and TCTP TG mice with DOX or normal saline (CTRL) treatment. Nuclei were stained with DAPI (blue). Representative images are shown to the left. The white arrows indicate apoptotic cells in the sections \( (n = 4 – 7) \). Scale bar, 50 μm. *\( P < 0.05 \), **\( P < 0.01 \), ***\( P < 0.001 \). Unpaired, two-tailed Student’s t-test \( (b) \) or two-way ANOVA followed by Bonferroni’s test \( (c-g) \).
Discussion

To our knowledge, this is the first report on the function of TCTP in the heart, although TCTP is known to play important roles in cell survival in a cell-type-dependent manner\textsuperscript{12,15,19,20}. Our results here support a pivotal role of TCTP in the maintenance of cardiomyocyte viability (Fig. S9). We also identified Bnip3 as a new player in TCTP-loss-induced cell death. TCTP downregulation by siRNA resulted in cardiomyocyte death, at least in part through a Bnip3-dependent mechanism (Fig. 3; Fig. S2 and S3).
Bnip3 is one of the pro-apoptotic members of the BH-3-only subfamily of Bcl-2 family proteins. Although there are several reports on the relationship between TCTP and Bcl-2 family proteins, such as Bax, Bcl-xl, MCL-1, etc. \textsuperscript{14}, this is the first report of the involvement of Bnip3 in TCTP-induced signaling. In accordance with this finding, TCTP-loss-induced cardiomyocyte death showed apoptotic and autophagic features accompanied with mPTP opening, resembling those reported in Bnip3-induced cell death.\textsuperscript{27,55}

To examine the mechanisms underlying TCTP-loss-induced cardiomyocyte death, we first investigated p53-induced signaling. It is reported that TCTP and p53 mutually downregulate each other’s expression in cancer cells\textsuperscript{53}, and p53 has been reported to play an important role in cardiac cell death\textsuperscript{2}. However, a positive relationship between the expression levels of TCTP and p53 was reported in non-cancer tissues.\textsuperscript{56} After TCTP siRNA treatment in NRVMs, we did not observe significant induction of p53 (Fig. S4b). In addition, protein expression of Bax (Fig. S4c), a pro-apoptotic protein, which is transactivated by p53, was rather suppressed by TCTP siRNA treatment. Notably, on the other hand, we observed the induction of Bnip3 in response to loss of TCTP (Fig. 3a, b; Fig. S3a). In addition, NF-κB, a negative regulator of Bnip3\textsuperscript{43}, was downregulated by TCTP siRNA treatment, suggesting that attenuation of the inhibitory effect of NF-κB on Bnip3 expression may be involved in the TCTP-loss-induced Bnip3 expression. At least in this experimental system, Bnip3 plays a more important role than p53 in TCTP-loss-induced cell death.

In exploring the clinical significance of the TCTP expression in the heart, we found that DOX treatment suppressed TCTP expression in cultured cardiomyocytes and mouse heart. In addition, exogenous supplementation of TCTP significantly inhibited DOX-induced cardiomyocyte death (Fig. 4). Importantly, just supplementary exogenous expression to rescue the DOX-induced reduction of TCTP expression was enough to significantly inhibit DOX-induced cardiomyocyte death. These findings indicate that the TCTP downregulation itself may contribute the cardiotoxicity of DOX.

In line with these findings, cardiomyocyte-specific overexpression of TCTP significantly inhibited DOX-induced Bnip3 expression and the development of cardiac dysfunction in mice. TCTP overexpression in cardiomyocytes caused no significant changes in cardiac function or morphology. However, after DOX treatment, development of cardiac dysfunction was significantly attenuated in cardiomyocyte-specific TCTP-overexpressing mice (Fig. 6; Fig. S8). These findings suggested that maintenance of TCTP levels in cardiomyocytes may be a novel therapeutic strategy to ameliorate or prevent DOX-induced heart failure.

To examine the mechanism of DOX-induced TCTP loss, we assessed the effect of DOX treatment on cardiac TCTP and Bnip3 expression in mice. p53 plays an important role in the development of DOX-induced heart failure\textsuperscript{41,51,52}, and as mentioned above, TCTP and p53 mutually downregulate each other’s expression\textsuperscript{53}. Our results support the idea that p53 is involved in the DOX-induced TCTP loss and enhancement of Bnip3 expression in mouse heart.

To investigate the effect of TCTP loss on cardiac function in vivo, we next examined the effect of DHA, a TCTP pharmacological inhibitor, on cardiac function\textsuperscript{16,34,35}. As expected, DHA treatment downregulated TCTP in the heart. In addition, DHA induced heart failure accompanied with an increase of apoptosis in cardiomyocytes, which were rescued by TCTP overexpression (Fig. 7). These findings indicate that the maintenance of TCTP expression may be important for cardiomyocyte survival and preservation of cardiac function. DHA is an established agent for the treatment of malaria infection.\textsuperscript{57} Recently, mouse and canine studies indicated that long-term DHA therapy has an anti-tumor effect\textsuperscript{58,59}, which appears to be due mainly to its pro-apoptotic action. To our knowledge, this is the first report regarding the effect of DHA on cardiac function. It may be important to consider this cardiac side effect, especially in patients receiving high-dose, long-term treatment with DHA. These findings suggest that maintenance of TCTP expression in cardiomyocytes would be important for the prevention of cardiomyocyte death and heart failure.

Several molecules such as p53\textsuperscript{53}, CREB\textsuperscript{60}, and chromodomain helicase/ATPase DNA binding protein 1-like gene (CHD1L)\textsuperscript{61} are reported to be involved in the regulation of TCTP expression. During the treatment of heart failure, signaling pathways that affect the functions of these proteins should be borne in mind. cAMP signaling is reported to upregulate TCTP expression in cancer cells.\textsuperscript{60} CREB-induced transactivation is involved here. The concentration of catecholamines in blood is increased in patients with heart failure\textsuperscript{62}. In accordance with this, cardiac TCTP expression was elevated in several mouse heart failure models, including a chronic catecholamine infusion model and the TAC model (Fig. S6). This response may act protectively against the development of heart failure by preventing stress-induced cardiomyocyte death. On the other hand, we can speculate that treatment with β-adrenergic receptor blockers, one of the established therapies for heart failure, may lead to a reduction of TCTP expression through its inhibitory effect on CREB function\textsuperscript{63}. Consideration of this possible adverse effect may be helpful in the development of new treatments to prevent cardiomyocyte death. Interestingly, miRNA-27b downregulates TCTP protein expression\textsuperscript{64}, and the therapeutic utility of miRNA inhibition by
modified antisenes oligonucleotides has been reported.\textsuperscript{65,66} Induction of TCTP expression in this way could be a candidate for heart failure therapy.

Our findings indicate that TCTP plays a pivotal role in cardiomyocyte survival, at least in part through a Bnip3-dependent mechanism. DOX-induced TCTP loss may be involved in the cardiotoxicity of DOX. TCTP may be a candidate therapeutic target to prevent DOX-induced heart failure.

Acknowledgements
This work was supported in part by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant (21790738 to T.F., 24390200, 25670131, 16H05300, and 16K15205 to Y.I.); the Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI Grant (22136009 to Y.I.); the New Energy and Industrial Technology Development Organization (NEDO) (60890002 to Y.I.); the National Cerebral and Cardiovascular Center (NCCV) (22-2-3 to Y.I.); the Japan Agency for Medical Research and Development (AMED) (66890005, 66890011, 66890001, 66890023, 66890003, 66890007, and 66891153 to Y.I.); Yokohama Foundation for Advancement of Medical Science (F.F.); we thank Naomasa Ichihara (Yokohama City University, Japan), Rajesh Prajapat (Yokohama City University, Japan), Hironori Yoshida (Yokohama City University, Japan) and Kei Kubota (Yokohama City University, Japan) for their technical assistance and animal care.

Author details
1 Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 2 Laboratories for Animal Resource Development, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan. 3 Laboratories for Genetic Engineering, RIKEN Center for Biosystems Dynamics Research, Kobe, Japan. 4 Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, Rutgers New Jersey Medical School, Newark, NJ, USA.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41419-019-1787-7)

Received: 26 March 2019 Revised: 10 June 2019 Accepted: 21 June 2019 Published online: 18 July 2019

References
1. Moe, G. W. & Marin-Garcia, J. Role of cell death in the progression of heart failure. Heart Fail Rev. 21, 157–167 (2016).
2. Fujita, T. & Ishikawa, Y. Apoptosis in heart failure. The role of the beta-adrenergic receptor-mediated signaling pathway and p53-mediated signaling pathway in the apoptosis of cardiomyocytes. Circ. J. 75, 1811–1818 (2011).
3. Fujita, T., Umemura, M., Yokoysama, U., Okumura, S. & Ishikawa, Y. The role of Epac in the heart. Cell Mol. Life Sci. 74, 591–606 (2017).
4. Okumura, S. et al. Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses. J. Clin. Invest. 124, 2785–2801 (2014).
5. Qin, W. et al. Disruption of Epac1 protects the heart from adenylyl cyclase type 5-mediated cardiac dysfunction. Biochem. Biophys. Res. Commun. 475, 1–7 (2016).
6. Nakamura, T. et al. Vldarabine, an anti-herpes virus agent, protects against the development of heart failure with relatively mild side-effects on cardiac function in a canine model of pacing-induced dilated cardiomyopathy. Circ. J. 80, 2496–2505 (2016).
7. Okumura, S. et al. Disruption of type 5 adenyl cyclase gene preserves cardiac function against pressure overload. Proc. Natl Acad. Sci. USA 100, 9986–9990 (2003).
8. Okumura, S. et al. Disruption of type 5 adenyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation 116, 1776–1783 (2007).
9. Jin, H. et al. Cardiac overexpression of Epac1 in transgenic mice rescues lipopolysaccharide-induced cardiac dysfunction and inhibits Jak-STAT pathway. J. Mol. Cell Cardiol. 108, 170–181 (2017).
10. Xiong, S., Van Pelt, C. S., Elzendoerfer, A. C., Fernandez-Garcia, B. & Lozano, G. Loss of Mdml4 results in p53-dependent dilated cardiomyopathy. Circulation 115, 2925–2930 (2007).
11. Naito, A. et al. Promotion of CHK-mediated p53 degradation protects the heart from ischemic injury. Circ. Res. 106, 1692–1702 (2010).
12. Susini, L. et al. TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ. 15, 1211–1220 (2008).
13. Li, F., Zhang, D. & Fujise, K. Characterization of fortilin, a novel antiapoptotic protein. J. Biol. Chem. 276, 47542–47549 (2001).
14. Azuma, J., Baydot, V., So, A. & Rocchi, P. TCTP as therapeutic target in cancers. Cancer Treat. Rev. 40, 760–769 (2014).
15. Chen, Y. et al. Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein. J. Biol. Chem. 286, 32575–32585 (2011).
16. Fujita, T. et al. Human fortilin is a molecular target of dihydroartemisinin. FEBS Lett. 582, 1055–1060 (2008).
17. Teleman, A. & Amson, R. The molecular programme of tumour reversion: the steps beyond malignant transformation. Nat. Rev. Cancer 9, 206–216 (2009).
18. Lavoie, J. et al. Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arteriolar hypertension. Circulation 129, 2125–2135 (2014).
19. Zhang, J. et al. Role of the translationally controlled tumor protein in DNA damage sensing and repair. Proc. Natl Acad. Sci. USA 109, E926–E933 (2012).
20. Gnanasekar, M., Thirugnanam, S., Zheng, G., Chen, A. & Ramsawamy, K. Gene silencing of translationally controlled tumor protein (TCTP) by siRNA inhibits cell growth and induces apoptosis of human prostate cancer cells. Int J. Oncol. 34, 1241–1246 (2009).
21. Chen, S. H. et al. A knockdown mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell-type-specific manner. Mol. Biol. Cell 18, 2525–2532 (2007).
22. Kaarbo, M. et al. TCTP is an androgen-regulated gene implicated in prostate cancer. PLoS ONE 8, e69938 (2013).
23. Boia-Ferreira, M. et al. TCTP as a therapeutic target in melanoma treatment. J. Cancer 117, 656–665 (2017).
24. Wang, L. et al. Knockdown of translationally controlled tumor protein inhibits growth, migration and invasion of lung cancer cells. Life Sci. 193, 292–299 (2018).
25. Wu, P. S. et al. Critical roles of translationally controlled tumor protein in the homeostasis and TCR-mediated proliferation of peripheral T cells. J. Immunol. 183, 2373–2381 (2009).
26. Gachet, Y. et al. The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J. Cell Sci. 112(Pt 8), 1257–1271 (1999).
27. Regula, K. M., Ens, K. & Kirchenbaum, L. A. Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ. Res. 91, 226–231 (2002).
28. Chiavegatte, A. & Hott. Potential role of BNIP3 in cardiac remodeling, myocardial stiffness, and endoplasmic reticulum: mitochondrial calcium homeostasis in diastolic and systolic heart failure. Circ. Heart Fail 6, 572–583 (2013).
29. Zhou, X. Z. et al. Isoprostrenol instigates cardiomyocyte apoptosis and heart failure via AMPK inactivation-mediated endoplasmic reticulum stress. Apop- tosis 18, 800–810 (2013).
30. Quinney, M. N. & et al. BNIP3 mediates permeabilization of mitochondria and release of cytochrome c via a novel mechanism. J. Mol. Cell Cardiol. 48, 1146–1156 (2010).
31. Kubasaki, L. A., Hernandez, O. M., Bishop, C. D. & Webster, K. A. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc. Natl Acad. Sci. USA 99, 12825–12830 (2002).
32. Dhingra, R. et al. BNip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proc. Natl Acad. Sci. USA 111, E5537–E5544 (2014).
33. Octavia, Y. et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell Cardiol. 52, 1213–1225 (2012).

34. Eichhorn, T. et al. Molecular interaction of artesiminin with translationally controlled tumor protein (TCTP) of Plasmodium falciparum. Biochem. Pharmac. 85, 38–45 (2013).

35. Lucibellos, M. et al. Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells. Oncotarget 6, 5275–5291 (2015).

36. Jin, H. et al. Epac activation inhibits IL-6-induced cardiac myocyte dysfunction. J. Physiol. 68, 77–88 (2017).

37. Jia, S. et al. Nogo-C regulates cardiomyocyte apoptosis during mouse myocardial infarction. Cell Death Dis. 7, e2403 (2016).

38. Mammucari, C., Schiafetta, G. G., & Hill, J. A. Therapeutic targeting of autophagy in cardiovascular disease. J. Mol. Cell Cardiol. 95, 86–93 (2016).

39. Li, D. L. et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation 133, 1668–1687 (2016).

40. Sano, M. et al. p53-induced inhibition of HIF-1 causes cardiac dysfunction during pressure overload. Nature 446, 444–448 (2007).

41. Matsusaka, H. et al. Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice. Cardiovacs Res. 70, 457–465 (2006).

42. Zhu, W. et al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119, 99–106 (2009).

43. Aviv, Y., Shaw, J., Gang, H. & Kirshenbaum, L. A. Regulation of autophagy in the heart: “you only live twice”. Antioxid. Redox Signal 14, 2245–2250 (2011).

44. Li, D. L. et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation 133, 1668–1687 (2016).

45. Sano, M. et al. p53-induced inhibition of HIF-1 causes cardiac dysfunction during pressure overload. Nature 446, 444–448 (2007).

46. Schiattarella, G. G. & Hill, J. A. Therapeutic targeting of autophagy in cardiovascular disease. J. Mol. Cell Cardiol. 95, 86–93 (2016).

47. Aviv, Y., Shaw, J., Gang, H. & Kirshenbaum, L. A. Regulation of autophagy in the heart: “you only live twice”. Antioxid. Redox Signal 14, 2245–2250 (2011).

48. Li, D. L. et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation 133, 1668–1687 (2016).

49. Sano, M. et al. p53-induced inhibition of HIF-1 causes cardiac dysfunction during pressure overload. Nature 446, 444–448 (2007).

50. Matsusaka, H. et al. Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice. Cardiovacs Res. 70, 457–465 (2006).

51. Shizukuda, Y., Matoba, S., Mian, O. Y., Nguyen, T. & Hwang, P. M. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol. Cell Biochem. 273, 25–32 (2005).

52. Zhu, W. et al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119, 99–106 (2009).

53. Montoya, A. et al. Use of non-selective beta-blockers is associated with decreased tumor proliferative indices in early stage breast cancer. Oncotarget 8, 6446–6460 (2017).

54. Li, D. L. et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation 133, 1668–1687 (2016).

55. Sano, M. et al. p53-induced inhibition of HIF-1 causes cardiac dysfunction during pressure overload. Nature 446, 444–448 (2007).

56. Schiattarella, G. G. & Hill, J. A. Therapeutic targeting of autophagy in cardiovascular disease. J. Mol. Cell Cardiol. 95, 86–93 (2016).

57. Aviv, Y., Shaw, J., Gang, H. & Kirshenbaum, L. A. Regulation of autophagy in the heart: “you only live twice”. Antioxid. Redox Signal 14, 2245–2250 (2011).

58. Li, D. L. et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation 133, 1668–1687 (2016).

59. Sano, M. et al. p53-induced inhibition of HIF-1 causes cardiac dysfunction during pressure overload. Nature 446, 444–448 (2007).

60. Matsusaka, H. et al. Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice. Cardiovacs Res. 70, 457–465 (2006).